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Objective: The effects of microRNA-20a (miR-20a) antisense oligonucleotides
(ASODNs) on the proliferation and apoptosis of K562 cells were investigated, and the
effects of these ASODNs in combination with imatinib on K562 cells were preliminarily
observed.
Methods: miR-20a ASODNs and scrambled oligonucleotides (SODNs) were chemically
synthesized, and the later was used as the control. miR-20a ASODNs were transfected
into K562 cells using Lipofectamine 2000 transfection reagent, and the expression of
miR-20a was detected using real-time quantitative RT-PCR (qRT-PCR). The CCK8 assay
was performed to detect the inhibition of the cell growth rate. The cells were stained by
Hoechst 33258 to detect apoptotic cell morphology. Annexin V/PI double staining was
used to detect the cell apoptosis rate using flow cytometry. The protein expression levels
of E2F1, P21, and Bim in the K562 cell line were detected using western blotting.
Results: The qRT-PCR results showed that the expression level of miR-20a in K562
cells transfected with miR-20a ASODNs was lower than those in the normal control,
SODN and blank transfection groups (p< 0.05). miR-20a ASODNs significantly inhibited
the growth of K562 cells as compared to the controls (p < 0.05). The Hoechst staining
results showed morphological changes, suggesting apoptosis. The cell apoptosis rates
in the ASODN group was (13.9 ± 1.5)%, which was significantly higher than that in the
normal control group (1.84 ± 0.21)%, blank transfection group (3.21 ± 0.32)%, and
SODN group (3.72 ± 0.44)% (p < 0.05). The protein expression of E2F1 and P21 in
K562 cells transfected with miR-20a ASODNs were higher, while the level of Bim protein
was significantly lower than that in the control groups. When miR-20a ASODNs were
combined with imatinib, the growth of K562 cells was significantly inhibited as compared
to the ASODN treatment alone, imatinib alone, and SODN+imatinib groups (p < 0.05).
Conclusions: miR-20a ASODNs could induce apoptosis and inhibit the proliferation
of K562 cells. In addition, imatinib combined with miR-20a ASODNs can increase the
inhibitory effect on K562 cell proliferation.
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INTRODUCTION
microRNAs (miRNAs) comprise a group of non-coding
small molecule RNAs. miRNA genes account for 1% of
the total human genome (Shao-Yao, 2007), yet they play
important regulatory roles in the physiological activities
of cells, such as growth, differentiation, proliferation, and
apoptosis. Accumulative literature data suggest that the
abnormal expression and regulation of miRNA are involved
in the development and progression of many types of tumors
(Croce, 2009). In addition, Analysis of miRNA expression
profiles in chronic myeloid leukemia (CML) patients and
healthy controls showed that the abnormal expression of
some miRNAs was closely associated with the abnormal
proliferation of CML cells (Venturini et al., 2007; Zhu et al.,
2014). Therefore, miRNAs are new targets for the diagnosis
and treatment of cancers, and open new avenues for cancer
therapy.
The miR-17-92 cluster genes are located in the third intron
of the C13orf25 gene on 13q31 and include miR-17-5p, miR-17-
3p, miR-18, miR-19a, miR-19b, miR-20a, and miR-92-1 isoforms.
They are closely associated with tumor development and are
highly expressed in solid tumors and malignant hematologic
disease (He et al., 2005; Fassina et al., 2012; Jin et al., 2013;
Scherr et al., 2014). It has been shown that the expression of
miR-17-92 cluster genes are increased in CD34+ cells in the
early chronic phase of CML through the BCR-ABL-c-MYC-miR-
17-92 pathway (Venturini et al., 2007). miR-20a belongs to
the miR-17-92 family and is abnormally expressed in various
tumors, such as lung cancer, gastric cancer, and colorectal cancer
(Zhang et al., 2014; Fuziwara and Kimura, 2015; da Silva Oliveira
et al., 2016). The high miR-20a expression can attenuate the
expression of PTEN to promote tumor development (Fuziwara
and Kimura, 2015). miR-20a is closely associated with the growth,
invasion, and metastasis of tumor cells (Huang et al., 2012;
Qiang et al., 2014; Zhang et al., 2014; Wang et al., 2015; Zhao
et al., 2015). The study by Zhang et al. (2014) showed that the
expression of miR-20a increased in colorectal cancer and was
closely associated with the lymph node and distant metastases.
In addition, high miR-20a expression could induce tumor
cell resistance to chemotherapeutic drugs through different
target genes (Chai et al., 2011; Zhu et al., 2016). Therefore,
downregulation of miR-20a may increase the sensitivity of tumor
cells to chemotherapeutic drugs.
Imatinib is a drug that specifically inhibits tyrosine kinase
activity in the CML fusion gene, BCR/ABL1. However, studies
have increasingly shown that drug insensitivity or drug
resistance occurs during treatment of CML using imatinib. It
is not clear whether downregulation of miR-20a expression
can enhance the inhibitory effect of imatinib on K562 cell
proliferation. Therefore, this study aimed to study the effects
of miR-20a downregulation on K562 cell proliferation and
apoptosis and changes in the expression of its related target
proteins. In addition, the effects of the combination of miR-
20a and imatinib on K562 cell proliferation were further
investigated to provide new insight for targeted treatment of
CML.
MATERIALS AND METHODS
Materials
The miRNA-20a antisense oligonucleotide (ASODN):
5′GUACCUGCACUAUAAGCACUUUA-3′ and the scrambled
sequence: 5′CAGUACUUUUGUGUAGUACAA-3′ were
synthesized by Shanghai GeneChem Co., Ltd., (China). Gibco
RPMI 1640 culture medium was purchased from HyClone
(USA). Lipofectamine 2000 Reagent was purchased from
Invitrogen (USA). Imatinib mesylate was purchased from Selleck
(USA). The CCK-8 Kit was purchased from ProbeGene Life
Sciences (China). The fluorescence quantitative PCR reagent kit
was purchased from RiboBio Co., Ltd., (China). Antibodies were
purchased from Abcam (USA).
Methods
Cell Culture and Transfection
K562 cells were maintained in RPMI-1640 culture medium
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin,
and 100 U/ml streptomycin and were continuously cultured in
an incubator with saturated humidity (37◦C and 5% CO2). The
medium was refreshed every other day. Cells at the logarithmic
growth phase were used for experiments. Transfection was
performed using the Lipofectamine 2000 transfection reagent
according to the instruction manual. The experimental cells
were divided into the miR-20a ASODN group, scrambled
oligonucleotides (SODNs) group, simple liposome group (blank
transfection group), and cell group (the blank group).
Detection of the Relative Expression Level of miR-20a
Using Fluorescence Real-Time Quantitative PCR
Cells were collected after 48 h of transfection. RNA was extracted
using the TRIzol reagent kit, and first strand cDNA was
synthesized by reverse transcription using random primers and
a reverse transcription reagent kit. The expression of miR-20a
was detected using the SYBR Green I dye method with U6
as the internal control. The total reaction volume was 20 µL.
The reaction condition was 95◦C 10min for pre-denaturation
followed by 40 cycles of amplification. Each amplification cycle
included 95◦C 2 s, 60◦C 30 s, and 70◦C 10 s. The plate was read
once at 70◦C. Next, the fluorescence values were recorded every
5 s from 70 to 95◦C at the changing rate of 0.5◦C/s to obtain
the melting curve. The relative expression levels in the cells were
calculated using the relative quantitative formula: 2−1Ct × 100%,
1Ct= Ct(miR-20a)−Ct(U6).
Detection of Cell Proliferation Using the CCK8
Method
K562 cells at the logarithmic growth phase were inoculated onto
96-well plates, and transfection was performed according to the
above procedures. At 48 and 72 h post transfection, 10µL of
CCK8 was added to each well and incubated at 37◦C for 4 h. The
absorbance (A450) at the wavelength of 450 nm were measured
in a microplate reader. The A450 value reflected the number of
surviving cells. After miR-20a ASODN transfection, cells were
treated with combined 0.6 µmol/L imatinib and cultured in an
incubator for 48 and 72 h. The A450 values of the cells in each
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group were measured, and the proliferation inhibition rates of
the cells were estimated by the equation: The cell proliferation
inhibition rate (%) = (1–A450 in the experimental group/A450
in the control group) × 100%. The experiments in each group
were repeated three times.
Observation of Apoptotic Cell Morphology Using
Hoechst 33258 Staining
After 72 h of transfection, cells were collected, centrifuged, and
fixed in 0.5ml of 4% formaldehyde solution for 10min. The cells
were then washed with PBS twice, the supernatant was discarded,
and the remaining liquid was aspirated using a pipette. Cells were
resuspended in 20 µL of DEPC water, evenly spread onto slides,
and naturally dried. The Hoechst 33258 staining solution was
evenly dropped onto slides, and staining proceeded for 5 min in
the dark. The slides were washed with distilled water (ddH2O)
twice, and excess water was soaked up to allow the slides to dry.
The slides were covered with clean cover slips, and the stained
cell morphology was observed under a fluorescence microscope.
Detection of Cell Apoptosis Rates Using Annexin V/PI
Double Staining and Flow Cytometry
Cells were centrifuged, collected, and washed with PBS twice. The
supernatant was discarded, and the cells were resuspended in 400
µL of 1 × Binding Buffer and incubated with 5 µL of Annexin
V-FITC for 15min in the dark. Cells were mixed thoroughly with
10µL of PI staining solution and incubated for 5min in the dark.
The cell apoptosis rate was detected using a flow cytometer.
Detection of the Expression of Target Proteins Using
Western Blotting
K562 cells in each group were collected in 1.5-ml centrifuge
tubes after 48 h of transfection. The total cellular protein
was extracted using a protein extraction kit (Sigma,USA) and
quantitated using the BCA method. The protein lysate (100
µl) was mixed with the sample loading buffer (1.0 M Tris-
HCl (pH 6.8) 1.0ml, 10% SDS 6.0ml, β-mercaptoethanol 0.2ml,
and ddH2O 2.8ml) and denatured at 100
◦C for 5min. Proteins
were separated in 10% SDS-PAGE and electrotransferred onto
a nitrocellulose membrane. The membrane was incubated with
primary antibodies (E2F1 1:200, P21 1:1,000–2,000, and Bim
1:500) at 4◦C overnight, and GADPH primary antibody was
used as the internal control. On the second day, the membrane
was incubated with secondary antibodies [GVPDH (mouse anti-
rabbit) 1:6,000, E2F1, P21, and Bim secondary antibodies 1:2,000]
at room temperature for ∼1 h on a shaker at 75 rpm. The
secondary antibodies were washed out with TBST. Developing
solution (Multi Sciences, China) was prepared at 1:1, and
the membrane was placed in a UV gel image analyzer and
photographed.
Statistical Analysis
SPSS13.0 software (SPSS Direct,Chicago) was used for the
statistical analysis of the data. Experimental data are expressed as
the mean± standard deviation. The comparison of data between
two groups was performed using a two-sample t-test. The
comparison of data among multiple groups was performed using
the analysis of variance of completely randomized design and
random block design. The comparison of differences between
groups was examined using the S-N-K test, which could perform
pairwise comparisons of mean values of multiple samples. α =
0.05 was used as the significance level, and P < 0.05 indicated
statistical significance.
RESULTS
Detection of miR-20a Expression in K562
Cells after Transfection Using qRT-PCR
Detection of miR-20a Expression Using qRT-PCR
After two-fold serial dilution of cDNA from the K562 cell line,
amplification of the target gene (miR-20a) and the internal
control gene (U6) was performed to make relative standard
curves. The correlation coefficients were 0.996 and 0.994 for
U6 and miR-20a, respectively. After the PCR reaction, the
melting curve peaks of U6 and miR-20a formed a specific single
peak. The peak values of the melting curves of the miR-20a
amplification products were all at 82.6◦C, and the peak values
of the melting curves of the U6 amplification products were
all at 82.7◦C. The amplification efficiencies of miR-20a and U6
were between 95 and 100%, demonstrating the consistency of
the amplification efficiencies for miR-20a and U6. Therefore, the
relative quantitation of miR-20a expression could be calculated
using the 2−1Ct × 100% formula.
miR-20a Expression Level in K562 Cells after
Transfection with miR-20a ASODNs
After K562 cells were transfected with miR-20a ASODNs for
48 h, the relative expression level of miR-20a was calculated using
the 2−1Ct× 100% formula (Figure 1). Compared to those in
the blank control group, blank transfection group, and SODN
group, the relative expression level in the ASODN group was
significantly downregulated (P< 0.05). No significant changes of
miR-20a expression were detected among the cell control group,
blank transfection group, and SODN group (P > 0.05).
K562 Cell Proliferation after Transfection
with miR-20a ASODNs
K562 cells were transfected with miR-20a ASODNs, and the cell
growth was detected using the CCK8 method (Figure 2). After
transfection for 48 and 72 h, cell proliferation in the ASODN
group was significantly inhibited, as compared to those in the
normal control group, blank transfection group, and SODN
group (Figure 2, P < 0.05). And, the difference of inhibition
between the 48 and 72 h treatment in the ASODN group had
statistical significance (P < 0.05). The cell control group, blank
transfection group, and SODN group were not significantly
different (P > 0.05).
Detection of Cell Apoptosis Morphology
Using Hoechst Staining
The Hoechst staining results showed that K562 cells exhibited
apoptotic morphological changes after miR-20a ASODN
transfection for 72 h. The K562 cells exhibited morphological
changes of apoptosis including decreased cell volume, nuclear
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FIGURE 1 | The effect of miR-20a ASODN transfection on the
expression level of miR-20a in K562 cells (*P < 0.05).
FIGURE 2 | Inhibition of K562 cell growth by miR-20a ASODN
(*P < 0.05).
condensation, and nuclear fragmentation. The K562 cells in the
cell control group, blank transfection group, and SODN group
did not exhibit apoptotic morphological changes (Figure 3).
Detection of Apoptosis Rates of K562 Cells
after miR-20a ASODN Transfection Using
Flow Cytometry
After K562 cells were transfected with miR-20a ASODNs for
48 h, the early-stage and late-stage apoptosis rates of cells were
detected using the Annexin V/PI double staining method and
flow cytometry. The results showed that the total apoptosis rate
of cells in the ASODN group significantly increased, and the
apoptosis rate was (13.86 ± 1.55)%, which was significantly
higher than those in the blank control group, blank transfection
group, and SODN group; the differences all had statistical
FIGURE 3 | Morphological changes of K562 cells after miR-20a ASODN
transfection for 72 h detected by Hoechst fluorescence stain (×400).
(A), ASODN group; (B), SODN group; (C), Blank transfection group; (D), Cell
control group.
significance (P < 0.05). The apoptosis rates in the latter three
groups were (1.84 ± 0.21), (3.21 ± 0.32), and (3.72 ± 0.44)%,
respectively, with no significant differences among the control
groups (P > 0.05) (Figure 4).
Detection of the Expression Levels of
miR-20a Target Proteins Using Western
Blotting
After the K562 cell line was transfected with miR-20a ASODNs
for 48 h, the expression levels of four proteins, the internal
control protein GAPDH and the target proteins, E2F1, P21, and
Bim, were detected using western blotting (Figure 5).The results
showed that the expression levels of E2F1 and P21 proteins in
the miR-20a ASODN group were higher than those in the cell
control group, blank transfection group, and SODN group, while
the expression level of Bim protein in themiR-20a ASODN group
was lower than that in the other three groups. The expression
level of the internal control protein was the same in all the groups.
The Inhibitory Effect of miR-20a ASODNs
Combined with Imatinib on the Growth of
K562 Cells
The cell growth rate of K562 cells transfected with miR-20a
ASODN transfection was measured using the CCK8 method
when cultured with 0.6 µmol/L imatinib (Figure 6). After
transfection for 48 and 72 h, cell proliferation in the group
with the combination of miR-20a ASODNs transfection and
imatinib incubation was significantly suppressed; compared to
that in the ASDON alone group, imatinib alone group, and
SODN+imatinib group (P < 0.05). In addition, with increasing
reaction time, the effect gradually increased. The comparison of
the results between 48 and 72 h showed that the difference had
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FIGURE 4 | Flow cytometric detection of K562 cell apoptosis after
miR-20a ASODN transfection for 48 h. (Annexin V/PI double staining
method; the figure was a representative result). (A), ASODN group; (B), SODN
group; (C), Blank transfection group; (D), Cell control group.
statistical significance (P< 0.05). The experiments were repeated
three times in each group.
DISCUSSION
It has been well-documented that miRNAs are involved in the
development and progression of a variety of tumors, including
hematologic tumors. ThemiR-17-92 cluster genes are abnormally
amplified in a variety of tumors and have carcinogenesis in
tumor cells (Hayashita et al., 2005; Fontana et al., 2008; Inomata
et al., 2009). Venturini et al. (2007) showed that compared to
normal CD34+ cells, CD34+ cells in the early chronic phase of
CML had significantly higher expression levels of the miR-17-
92 cluster genes. They also showed that c-Myc could regulate the
expression of the miRNA-17-92 cluster genes, while c-Myc could
be activated by the product of the BCR-ABL genes. In addition,
they compared the expression of 210 miRNAs in K562 cells
using the miRNA microarray method. The results showed that
the expression of the mature miR-17-92 cluster genes decreased
followed by the BCR-ABL kinase activity being suppressed by
imatinib or the BCR-ABL expression being downregulated by
RNAi. In addition, the inhibition of K562 cell proliferation
and survival by downregulation of Myc by RNAi could be
partially blocked by lentivirus-mediated overexpression of miR-
17-19b-1, the other member of the miR-17-92 cluster family.
Therefore, the miR-17-92 cluster family may be closely associated
with CML. The results in this study showed that miR-20a, an
isoform of miR-17-92 cluster genes was highly expressed in K562
cells.
In this study, after K562 cells were transfected with miR-20a
ASODNs, the expression level of miR-20a significantly decreased,
and K562 cell proliferation was significantly inhibited. In
FIGURE 5 | The expression of miR-20a target proteins after K562 cells
were transfected with miR-20a ASODNs for 48 h.
FIGURE 6 | The inhibitory effect of miR-20a ASODNs combined with
imatinib on the growth of K562 cells (*P < 0.05).
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addition, the effects appeared to be time-dependent. Therefore,
our results indicated that miR-20a ASODNs could specifically
inhibit K562 cell proliferation. The Hoechst staining results
showed that after K562 cells were transfected with miR-
20a ASODNs, the cells exhibited morphological changes of
apoptosis, such as decreased cell volume, nuclear condensation,
and nuclear fragmentation. In addition, the apoptosis rate
of K562 cells significantly increased after miR-20a ASODN
transfection. Therefore, these results indicated that miR-20a
ASODNs could promote K562 cell apoptosis, leading to the
inhibition of cell proliferation. Matsubara et al. (2007) used
ASODN to inhibit miR-17-5p and miR-20a, which caused
apoptosis in lung cancer cells that expressed high levels
of miR-17-92. The study of Dereani et al. (2014) also
showed that ASODN targeting miR-17, the other member of
the miR-17-92 cluster, could inhibit the growth of chronic
lymphocytic leukemia (CLL) in vivo and in vitro. Our study
results were consistent with the results reported in the above
literature.
To investigate the molecular mechanism underlying the
inhibition of K562 cell proliferation by miR-20a ASODNs,
we further monitored the expression of the miR-17-92 target
proteins E2F1 (O’Donnell et al., 2005), P21 (Inomata et al., 2009;
Wong et al., 2010), and Bim (Mavrakis et al., 2010) using western
blotting after the miR-20a in K562 cells was down-regulated by
ASODNs. E2F1 regulates the transition of cells from the early
G0/G1 phase to the S phase and can promote cell apoptosis;
therefore, it is an important cell cycle regulator. O’Donnell
et al. (2005) showed that c-Myc regulated proliferation signals
through the activation of E2F1 transcription and regulation of
its translation. c-Myc is a well-known transcription factor closely
associated with the oncogenic function of the miRNA-17-92
family. Our results showed that after transfection with miR-20a
ASODNs, the expression level of E2F1 protein in K562 cells
significantly increased, suggesting that miR-20a in K562 cells
may target E2F1 gene expression regulation to promote cell
proliferation.
As a negative regulator of the cell cycle, P21 is closely
associated with the cell cycle, differentiation, aging, and apoptosis
and mediates the activity of transcription factors. In an MLL
leukemia animal model, the miR-17-92 cluster regulated the
pathogenic ability of leukemia stem cells through regulating the
expression of the cell cycle factor P21 (Wong et al., 2010). miR-
17 and miR-20a, which have conserve high gene hemology in
the miR-17-92 cluster, could promote the proliferation of CML
cells and B cell lymphoma cells through targeted regulation
of P21 expression (Inomata et al., 2009). The results in this
study showed that the expression level of P21 protein in
K562 cells in the ASODN significantly increased after miR-20
ASODN transfection, suggesting that miR-20a ASODNs induced
K562 cell apoptosis. The inhibition of cell proliferation may
be associated with the targeted regulation of P21 protein by
miR-20a.
The Bim (Bcl-2 interacting mediator of cell death) gene is
a tumor suppressor (Bouillet et al., 2001). Yan et al. showed
that inhibition of miR-17-5p expression upregulated the protein
expression level of its target gene, Bim, to increase the sensitivity
of pancreatic cells to gemcitabine (Yan et al., 2012). This study
showed that the expression level of Bim protein in K562 cells
transfected with miRNA-20a ASODNs significantly decreased,
which was not consistent with the expected results. This result
suggested that Bim in K562 cells may not be directly regulated
by miR-20a; further studies are warranted to elucidate the
mechanism.
This study further investigated the effect of miR-20a ASODNs
combined with imatinib on K562 cell proliferation. The CCK8
detection results showed that miR-20a ASODNs combined with
imatinib significantly inhibited K562 cell growth as compared to
the growth of the miR-20a ASODN alone, imatinib alone, and
SODN+imatinib groups. Therefore, miR-20a ASODNs along
with imatinib could increase the inhibitory effects on K562
cell proliferation. Lopotová et al. (2011) noted that tyrosine
kinase inhibitors (TKIs) such as imatinib could inhibit bcr-
abl expression to increase miR-451 expression. The destruction
of the regulatory loop between bcr-abl and miR-451 may help
to increase the treatment efficacy in CML patients. Liu et al.
(2012) showed that after CML cells were transfected with miR-
144/451, the apoptosis-inducing effect of imatinib was promoted
to overcome drug resistance to imatinib. The above literature
reports together with our findings demonstrated that miRNA
expression changes were closely associated with the sensitivity of
CML cells to imatinib.
Collectively, we concluded that miR-20a ASODNs can induce
K562 cell apoptosis and inhibit K562 cell proliferation. In
addition, miR-20a ASODN, in combination with imatinib, results
in an enhanced inhibiting effect on the proliferation of K562
than miR-20a ASODN or imatinib alone. The function of miR-
20a ASODNs in the inhibition of K562 cell proliferation may be
associated with the up-regulation of the target proteins E2F1 and
P21, which are regulated by miR-20a.
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